COMPOSITION FOR PRESERVING PLATELETS AND METHOD OF USING THE SAME

• US 20110223662A1
• Filed: 04/29/2011
• Published: 09/15/2011
• Est. Priority Date: 01/12/2005
• Status: Active Grant

• Current Assignee: Biovec Transfusion LLC
• Original Assignee: Biovec Transfusion LLC
• Inventors: Sehgal, Lakshman R.
• Granted Patent: US 8,329,389 B2
• Time in Patent Office: Days
• US Class Current: 435/374
• CPC Class Codes: A01N 1/02 Preservation of living parts
• CPC Class Codes: A01N 1/0215 Disinfecting agents, e.g. antimicrobials for preserving living parts
• CPC Class Codes: A01N 1/0226 Physiologically active agents, i.e. substances affecting physiological processes of cells and tissue to be preserved, e.g. anti-oxidants or nutrients

Abstract

The present invention relates to compositions and methods for storing platelets to preserve the function and freshness of the platelets. More particularly, the present invention relates to the use of a preservative composition having an antiplatelet agent, an anticoagulant, and an oxygen carrier, for maintaining the freshness of platelets. Additionally, the composition may also contain an ultra-short acting broad spectrum anti-microbial agents. The preservative composition may be used to store platelets in a liquid state, a frozen state, or a freeze-dried state.

Claims

1. A platelet preservation composition, comprising:

a) an antiplatelet agent;

b) an anticoagulant; and

c) an oxygen carrier;

wherein said antiplatelet agent comprises a short-to-ultrashort GPIIb/IIIA inhibitor, wherein said anticoagulant comprises a short-to-ultrashort acting factor Xa inhibitor and wherein said composition is capable of extending the shelf-life of a platelet.

4. The composition of claim 1, wherein said antiplatelet agent is selected from the group consisting of DUP728, XJ757, XR299, eptifibatide, orbofiban, xemilofiban, Lamifiban, tirofiban (Aggrastat), and mixtures thereof.

5. The composition of claim 1, wherein said antiplatelet agent is selected from the group consisting of linear and cyclic RGD analogs.

6. The composition of claim 5, wherein said linear and cyclic RGD analogs are conjugated to a nitric oxide donor.

7. The composition of claim 1, wherein said antiplatelet agent is a pharmaceutically acceptable antiplatelet agent and has a circulating half-life of inhibition of about less than 4 hours.

8. The composition of claim 1, wherein comprising said antiplatelet agent in an amount of about 0.001 mg to about 5 mg per 50 ml.

9. The composition of claim 1, wherein said anticoagulant is a compound that reversibly inhibits factor Xa.

10. The composition of claim 9, wherein said anticoagulant is a short-to-ultrashort acting Xa inhibitor with a circulating half-life of less than 4 hours.

11. The composition of claim 10, wherein said anticoagulant is selected from the group consisting of DX-9065a, BX-80783, and RPR-1208.

13. The composition of claim 1, wherein said anticoagulant is further comprises a short-to-ultrashort acting IIa inhibitor, and at least one short to ultrashort acting Xa inhibitor.

15. The composition of claim 1, wherein said oxygen carrier is a pharmaceutically acceptable oxygen carrier and is selected from the group consisting of hemoglobin, ferroprotoporphyrin, perfluorochemicals, and mixtures thereof.

16. The composition of claim 15, wherein said oxygen carrier is a hemoglobin-based oxygen carrier.

17. The composition of claim 16, wherein said hemoglobin-based oxygen carrier is substantially free of red cell membrane contaminants.

18. The composition of claim 1, further comprising a short-to-ultrashort acting broad spectrum anti-microbial agent.

19. The composition of claim 18, wherein said short-to-ultrashort acting anti-microbial agent is selected from the group consisting of:

Penicillin, Natural penicillins, Semisynthetic penicillins, Monobactam, Cephalosporin Carbapenems Vancomycin, Isoniazid (INH), Ethambutol, Aminoglycoside, Tetracycline, Chloramphenicol, Macrolide, Rifamycin, Quinolone, Fluoroquinolone, Sulfonamide, Synergism, Polyene antibiotic, Imidazole, Triazole, Griseofulvin and combinations thereof.

26. The composition of claim 1, comprising said anticoagulant in an amount of about 0.001 mg to about 5 mg-per 50 ml.

2-3. -3. (canceled)

12. (canceled)

14. (canceled)

20. A method of extending the shelf-life of platelets, comprising the steps of:

(a) admixing a preservative composition with inactivated, functional platelets to provide a preserved platelet composition; and

(b) store the preserved platelet composition in an oxygen-permeable container or an oxygen-impermeable container,

wherein the preservative composition comprises an antiplatelet agent, an anticoagulant, and an oxygen based carrier, wherein said antiplatelet agent comprises a short-to-ultrashort acting GPIIb/IIIA inhibitor, and wherein said anticoagulant comprises a short-to-ultrashort factor Xa inhibitor.

23. The method of claim 20, wherein said oxygen carrier is a pharmaceutically acceptable oxygen carrier and is selected from the group consisting of hemoglobin, ferroprotoporphyrin, perfluorochemicals, and mixtures thereof.

24. The method of claim 23, wherein said oxygen carrier is a hemoglobin-based oxygen carrier.

21-22. -22. (canceled)

25. (canceled)